Matthew Luchini
Stock Analyst at BMO Capital
(2.03)
# 3,057
Out of 5,131 analysts
35
Total ratings
44.44%
Success rate
6.45%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Luchini
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REPL Replimune Group | Maintains: Outperform | $51 → $30 | $7.98 | +275.94% | 4 | Mar 18, 2022 | |
| JSPR Jasper Therapeutics | Initiates: Outperform | $190 | $1.14 | +16,566.67% | 1 | Oct 20, 2021 | |
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $89 → $69 | $21.70 | +217.97% | 3 | Sep 10, 2021 | |
| KOD Kodiak Sciences | Maintains: Market Perform | $138 → $104 | $22.07 | +371.23% | 3 | May 11, 2021 | |
| CCCC C4 Therapeutics | Initiates: Outperform | $55 | $1.89 | +2,810.05% | 1 | Mar 31, 2021 | |
| ARVN Arvinas | Initiates: Outperform | $101 | $11.65 | +766.95% | 2 | Mar 31, 2021 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Outperform | $630 | $803.17 | -21.56% | 13 | Jan 25, 2021 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Market Perform | $119 → $124 | $464.71 | -73.32% | 2 | Nov 6, 2020 | |
| GILD Gilead Sciences | Maintains: Market Perform | $74 → $64 | $154.98 | -58.70% | 2 | Oct 29, 2020 | |
| VKTX Viking Therapeutics | Initiates: Outperform | $14 | $29.00 | -51.72% | 1 | Jun 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $47 → $60 | $1.13 | +5,209.73% | 2 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $28 → $14 | $10.29 | +36.05% | 1 | Aug 15, 2018 |
Replimune Group
Mar 18, 2022
Maintains: Outperform
Price Target: $51 → $30
Current: $7.98
Upside: +275.94%
Jasper Therapeutics
Oct 20, 2021
Initiates: Outperform
Price Target: $190
Current: $1.14
Upside: +16,566.67%
Apellis Pharmaceuticals
Sep 10, 2021
Maintains: Outperform
Price Target: $89 → $69
Current: $21.70
Upside: +217.97%
Kodiak Sciences
May 11, 2021
Maintains: Market Perform
Price Target: $138 → $104
Current: $22.07
Upside: +371.23%
C4 Therapeutics
Mar 31, 2021
Initiates: Outperform
Price Target: $55
Current: $1.89
Upside: +2,810.05%
Arvinas
Mar 31, 2021
Initiates: Outperform
Price Target: $101
Current: $11.65
Upside: +766.95%
Regeneron Pharmaceuticals
Jan 25, 2021
Upgrades: Outperform
Price Target: $630
Current: $803.17
Upside: -21.56%
Madrigal Pharmaceuticals
Nov 6, 2020
Maintains: Market Perform
Price Target: $119 → $124
Current: $464.71
Upside: -73.32%
Gilead Sciences
Oct 29, 2020
Maintains: Market Perform
Price Target: $74 → $64
Current: $154.98
Upside: -58.70%
Viking Therapeutics
Jun 5, 2020
Initiates: Outperform
Price Target: $14
Current: $29.00
Upside: -51.72%
Dec 3, 2019
Downgrades: Market Perform
Price Target: $47 → $60
Current: $1.13
Upside: +5,209.73%
Aug 15, 2018
Maintains: Market Perform
Price Target: $28 → $14
Current: $10.29
Upside: +36.05%